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Abstract: The JAK/STAT pathway is important for cellular metabolism. One component, STAT5a, is activated in the breast 
upon prolactin to prolactin receptor (PRLR) binding facilitating the transcription of genes involved in lobule development. 
STAT5a was previously found to be expressed in most normal breast epithelial cells but not in many in situ or invasive 
carcinomas except secretory carcinomas which retain STAT5a expression. This report examines the JAK/STAT pathway in 
the breast through the detection of PRLR and STAT5a. Fifty breast tissues, including benign secretory change, microglan-
dular adenosis, usual and atypical hyperplasia and in situ and invasive ductal carcinoma both usual and secretory, were 
obtained from the ﬁ  les of the Armed Forces Institute of Pathology. Sections were immunostained with antibodies to PRLR 
and STAT5a. PRLR was minimally detected on the surface of a few normal breast epithelial cells whereas STAT5a was 
greatly expressed in over 80% of normal cell nuclei. PRLR was also minimally detected in secretory carcinomas expressing 
STAT5a. However, the opposite pattern was seen in breast carcinomas lacking STAT5a expression. PRLR was abundantly 
expressed in these cells. This reversed expression may indicate a JAK/STAT pathway disturbance that could play a role in 
the initiation or maintenance of an abnormal breast phenotype.
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Introduction
The seven signal transducer and activator of transcription (STAT) molecules are effectors of hormonal and 
cytokine stimulation through the transcription of a variety of regulatory and differentiation proteins. The 
STATs are activated through the signaling of receptor-ligand complexes. One of the STAT proteins, STAT5a, 
is found in many cell types including breast epithelial cells where it is activated by the binding of prolactin 
to the prolactin receptor (PRLR). Activated STAT5a then undergoes dimerization, nuclear transport, and 
DNA binding, facilitating the transcription of genes involved in lobule development and mammary gland 
differentiation (Clevenger, 2004). STAT5a-deﬁ  cient transgenic mice develop normally, except for defec-
tive mammary gland development (Akira, 1999) and signaling via the PRLR through STAT5a is essential 
for lobuloalveolar growth and differentiation during pregnancy (Myoshi et al. 2001).
Using a monoclonal antibody, we have shown in formalin-ﬁ  xed, parafﬁ  n-embedded, breast tissue 
ranging from simple hyperplasia to invasive carcinoma that a direct correlation exists between abnor-
malities in breast epithelial cells and reduction in STAT5a expression, with STAT5a expression being 
decreased in ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (Bratthauer et al. 2006). 
The reduction of STAT5a may result in aberrant signaling of developmental or regulatory proteins, 
contributing to altered (metaplastic or neoplastic) differentiation. Cells undergoing secretory change 
over-express STAT5a. Surprisingly, secretory carcinomas of the breast maintain STAT5a expression, 
differing from other potential mimics such as apocrine metaplasia and mucinous or clear cell carcino-
mas, none of which expressed STAT5a in this study (Strauss et al. 2006).
Whether STAT5a affects the maintenance of the normal breast phenotype, as it does the establish-
ment of that phenotype, is subject to conjecture. The Janus kinase (JAK)/STAT pathway is important 
to cell development and differentiation; defects can lead to inhibition of growth restraint, with prolac-
tin implicated in the pathogenesis of human breast cancer (Clevenger et al. 2003). Because the JAK/STAT 
pathway is integral to the function of normal breast epithelial cells, abnormalities in this pathway 8
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between prolactin and STAT5a could play a role 
in the initiation or maintenance of carcinoma. This 
report examines this pathway by comparing PRLR 
and STAT5a expression patterns in benign and 
malignant examples of secretory and non-secretory 
breast epithelium.
Materials and Methods
Fifty formalin-ﬁ  xed, parafﬁ  n-embedded, tissues 
representing varying breast disease were obtained 
from the ﬁ  les of the Armed Forces Institute of 
Pathology (AFIP). All material was part of research 
protocols approved by the AFIP’s Institutional 
Review Board. The samples included usual and 
atypical ductal hyperplasia, microglandular adeno-
sis, in situ and invasive ductal carcinoma, secretory 
carcinoma, and those exhibiting secretory/lacta-
tional change. Most of the samples also contained 
normal terminal duct lobular units (TDLU). Tissues 
were selected based on STAT5a results obtained 
previously (Bratthauer et al. 2006). Tissues 
expressing and not expressing the STAT5a protein 
were assayed with antibody-optimized immuno-
histochemical protocols (Bratthauer, 1999) using 
antibodies to PRLR and STAT5a. Brieﬂ  y, 6 micron 
sections were heated for 30 minutes at 70 °C and 
then deparafﬁ  nized along with antigen enhance-
ment in a solution of Reveal (Biocare Medical 
Corporation, Concord, CA) in a pressure cooker 
for 3 minutes at 20 psi added pressure. Endogenous 
oxidative compounds were quenched with a 30 
minute incubation in 10% H2O2 in methanol. 
Monoclonal antibody ST5a-2H2 reactive against 
STAT5a (Zymed Laboratories, South San Francisco, 
CA), and monoclonal antibody B6.2, reactive 
against PRLR (Neomarkers, Lab Vision Corpora-
tion, Fremont CA), diluted 1:400 and 1:100 respec-
tively in TBS Plus (Biocare) with 0.1% Tween 20 
(DakoCytomation, Carpinteria, CA) (TBST), were 
applied to the sections for 60 minutes at room 
temperature. Concentrations were determined by 
serial dilution on known positive specimens. 
Detection was with the Elite Avidin-Biotin 
Complex (ABC) system (Vector Laboratories, 
Burlingame CA) using biotinylated horse anti-
mouse/rabbit IgG followed by ABC reagent 
applied for 45 minutes each with intervening rinses 
of TBST. Development occurred for 12 minutes 
using 0.08% diaminobenzidine tetrahydrochloride 
(Sigma Chemical Co., St. Louis, MO) with 0.024 
H2O2 (Sigma). Sections were counterstained with 
hematoxylin, dehydrated in ethanol, and mounted 
in Permount (Fisher Scientific Corporation, 
Pittsburgh, PA) following immersion in xylene. 
Simultaneous identiﬁ  cation of PRLR and STAT5a 
was performed by double-labeling immunohisto-
chemistry as described earlier (Bratthauer et al. 
2002). Diluted normal sera in substitution for the 
primary antibody served as a negative control. 
Selected positive and negative tissues were ana-
lyzed with alternate antibodies, a polyclonal rabbit 
antiserum directed against STAT5a (L-20, Santa 
Cruz Biotechnology Inc, Santa Cruz, CA, diluted 
1:100) and anti-PRLR clone SPM213 (Abcam Inc., 
Cambridge, MA, undiluted).
To assess the speciﬁ  city for STAT5a, a STAT5a 
peptide (Neomarkers, LabVision) was added to 
antibody ST5a-2H2 and allowed to incubate prior 
to antibody application. Graded concentrations of 
protein (0.1, 1.0 and 10 ug/ml) were added to anti-
body solutions which were incubated at 37  °C 
overnight, then centrifuged at 6000 rpm for 5 min-
utes and applied to STAT5a positive control tissue 
sections. A non-related protein was used in paral-
lel absorption experiments as a control.
To assess the efﬁ  cacy of the PRLR detection, 
enzyme enhanced antigen pretreatments were com-
pared to the above method of heat retrieval in a 
pressure cooker. Both pepsin (Sigma), at 1.0 mg/ml 
for 10 minutes at 37 °C in a Tris-HCl pH 2 solution, 
and protease VIII (Sigma), at 0.01 g/ml in TBST at 
37 °C for 5 minutes, were used as alternate 
pretreatments following tissue rehydration.
Assayed sections were examined for extent 
of immunostaining in a double-blind fashion by 
two of us (GLB, BLS). Tissues were scored as 
a product of intensity and distribution. Intensity 
was scored as 1+ (weak), 2+ (moderate), or 3+ 
(strong). The intensity score was multiplied by 
a distribution score of 1+ (5%–10%), 2+ (11%– 
40%), 3+ (41%–75%), or 4+ (76%–100%), to 
arrive at a semi-quantitative immunoscore 
ranging from 0 to 12.
Results
The results are listed in Table 1. The expression of 
STAT5a corresponded to earlier studies (Bratthauer 
et al. 2006) with the majority of normal lobular 
and ductal epithelial cells demonstrating STAT5a 
in the cytoplasm and nucleus (Fig. 1A). The cells 
of usual ductal hyperplasia and microglandular 
adenosis also expressed STAT5a and internal 9
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controls of adipose tissue, endothelial cells, and 
lymphocytes always showed reactivity. STAT5a 
expression was occasionally reduced in larger ducts 
and cells undergoing apocrine differentiation did 
not show any STAT5a expression.
In contrast, normal epithelium, along with usual 
ductal hyperplasia and microglandular adenosis, 
generally showed only minimal detectable PRLR 
(Fig. 1B), present as the luminal surface labeling 
of occasional cells. Neutrophils, endothelial cells, 
and smooth muscle cells (which normally show 
cytoplasmic PRLR) (Camarillo et al. 2001; 
Dogusan et al. 2001; Merkle et al. 2000; Nowak 
et al. 1999) were reactive and served as internal 
controls. Cells undergoing apocrine differentiation 
demonstrated cytoplasmic PRLR reactivity as did 
scattered myoepithelial cells in larger ducts.
As was shown previously, abnormal breast 
epithelium does not generally express the STAT5a 
protein using antibody ST5a-2H2 (Bratthauer et al. 
2006). For this study, specimens previously shown 
to have ADH, DCIS, or invasive carcinoma only 
minimally expressing STAT5a (mean immu-
noscores 1.0–1.2) were examined for PRLR. Epi-
thelial cells that essentially lacked STAT5a showed 
abundant PRLR expression in the cytoplasm as 
well as the cell membrane (Figs. 2 and 3), with 
mean immunoscores ranging from 10.4 to 11.0.
Secretory carcinomas tend to retain STAT5a 
expression (Strauss et al. 2006), and specimens 
Table 1. Relationship between STAT5a expression and PRLR expression in various breast epithelial cells.
Type #  Total  STAT5a  PRLR
    # Positive  Mean IS  # Positive  Mean IS
Usual Ductal Hyperplasia  3  3  10.7  3  3.0
Microglandular  Adenosis  1  1 4 0 0
Atypical Ductal Hyperplasia  2  1  1.0  2  10.5
Ductal Carcinoma in Situ  9  4  1.2  9  11.0
Invasive Ductal Carcinoma  20  8  1.0  20  10.4
Benign Secretory Changes  7  7  11.4  4  1.2
Secretory Breast Carcinoma  8  8  9.2  3  2.7
Immunoscore (IS) = intensity score × distribution score (range of 0–12).
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Figure 1. A) Immunohistochemical demonstration of STAT5a in the cytoplasm and nucleus of normal breast TDLU (200X). B) Immunohisto-
chemical demonstration of PRLR in this TDLU (200X). PRLR reactivity is mainly associated with endothelial cells and neutrophils (arrow).10
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with either benign secretory change or secretory 
carcinoma (mean STAT5a immunoscores of 11.4 
and 9.2, respectively) demonstrated greatly reduced 
PRLR (mean immunoscores of 1.2 and 2.7, 
respectively) (Fig. 4).
In almost all the cases examined, both normal 
and abnormal epithelia expressed either STAT5a 
or PRLR, with only a few cells expressing either 
both proteins or neither protein. This was highlighted 
by two-color simultaneous labeling (Fig. 5). All 
negative controls were non-reactive.
Assays with alternate antibodies to STAT5a and 
PRLR (L20 and SPM213, respectively) essentially 
demonstrated these same patterns of reactivity (data 
not shown) with antibody L20 exhibiting slightly 
increased background staining.
In addition, alternate methodology for detecting 
PRLR employing either protease or pepsin digestion 
Figure 2. A) H&E stain of invasive ductal carcinoma of the breast (top) adjacent to normal duct (bottom) (200X). B) Immunohistochemical 
demonstration of STAT5a expression (200X). C) Immunohistochemical demonstration of PRLR expression (200X). STAT5a is expressed in 
the normal duct and absent in the invasive ductal carcinoma; in contrast, PRLR is expressed in the invasive ductal carcinoma and absent 
in this normal duct.
Figure 3. A) H&E stain of invasive ductal carcinoma of the breast (400X) with occasional entrapped normal ducts (arrow). B) Immunohis-
tochemical demonstration of STAT5a in normal ducts (arrow) and scattered endothelial cells and lymphocytes (400X). STAT5a is absent in 
the tumor cells. C) Immunohistochemical demonstration of PRLR in the invasive ductal carcinoma (400X). Entrapped normal ducts show 
reduced PRLR expression (arrow).11
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showed the same reactivity patterns as the heat and 
pressure antigen recovery method. Preincubation 
with peptide demonstrated that STAT5a peptide 
added at 0.1ug/ml to ST5a-2H2 effectively extin-
guished all STAT5a observed reactivity, while a 
non-related protein added at up to 10 ug/ml had no 
effect (data not shown).
Discussion
Prolactin regulates mammary gland development 
during organogenesis, pregnancy and lactation 
(Horseman, 1999). In the breast it activates 
STAT5a, necessary for normal lobular growth. We 
have previously shown STAT5a expression reduced 
in many abnormal and malignant breast duct 
epithelial cells (Bratthauer et al. 2006) and were 
interested in further investigating the prolactin-
initiated JAK/STAT pathway and its relationship 
to abnormal breast epithelial cell growth.
In examining normal and hyperplastic breast 
epithelium, we noted that where STAT5a was 
present immunohistochemically, PRLR expression 
was much diminished. Conversely, in most 
Figure 4. A) H&E stain of secretory carcinoma of the breast (400X). B) Immunohistochemical demonstration of retained STAT5a (400X). 
C) Immunohistochemical detection of diminished PRLR expression in this secretory carcinoma (400X). Arrow denotes neutrophil control.
Figure 5. A) H&E stain of invasive ductal carcinoma, NOS (400X), showing normal cells with secretory change (left) adjacent to invasive 
tumor (right). B) Simultaneous immunohistochemical demonstration of STAT5a (brown) and PRLR (purple) as they are expressed in these 
normal and abnormal cells (400X).12
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abnormal or malignant breast epithelial cells, 
wherever STAT5a was absent, PRLR was markedly 
increased. A consistent exception was found in 
secretory carcinomas of the breast; these paralleled 
normal and hyperplastic breast epithelial cells in 
STAT5a and PRLR expression.
Antibody ST5a-2H2, recognizing STAT5a, 
reacts with the nuclei of most normal breast 
epithelial cells, and only rarely so with abnormal 
epithelium (Bratthauer et al. 2006). As outlined 
previously, published accounts vary in the degree 
of STAT5a positivity reported in human breast 
cancer, with one study indicating a 17% positivity 
rate for STAT5a in breast cancers (Nevalainen et al. 
2004) (approximating the rate found in our article), 
and another demonstrating STAT5a in 76% (Cotarla 
et al. 2004). In this current paper, the speciﬁ  city of 
the STAT5a immunostaining proﬁ  le is supported 
by demonstration of essentially the same pattern 
with an alternate antibody (L20), as well as the 
blocking of all reactivity with a STAT5a peptide.
Antibody B6.2 has been shown to identify 
PRLR in formalin-ﬁ  xed, parafﬁ  n-embedded, breast 
tissues (Gill et al. 2001). Using this and other 
antibodies, researchers have identified PRLR 
expression to some degree in most human breast 
cancers and normal breast tissue, on the luminal 
surface (Gill et al. 2001; Reynolds et al. 1997; 
Mertani et al. 1998). In the present study, although 
some luminal staining was observed in normal 
breast epithelium, a much stronger reactivity in 
DCIS and invasive carcinoma was observed 
throughout the cytoplasm and sometimes distinctly 
on the entire cell surface. The pattern was also 
observed with a different antibody (SPM213) using 
multiple different antigen retrieval methods, 
supporting the speciﬁ  city of the PRLR immuno-
proﬁ  le obtained here. That this pattern differs from 
some earlier reports is likely due in part to differ-
ences between antibody speciﬁ  cities. Antibody U6 
recognizes the extracellular domain of PRLR 
(Reynolds et al. 1997) while in another study a 
polyclonal goat antiserum showed partially 
perinuclear staining in normal and pregnant rats 
(Camarillo et al. 2001). Variable antigen speciﬁ  c-
ity may be the cause as well since PRLR exists in 
several functional isoforms (Clevenger et al. 2003; 
Reynolds et al. 1997; Trott et al. 2003). Alternate 
patterns of reactivity can also stem from what was 
interpreted as positive immunostaining; in this 
report we have made a distinction between the 
often faint luminal expression of PRLR seen in 
normal breast tissue of the type previously reported 
(Gill et al. 2001) and the much stronger cytoplasmic 
immunostaining observed in most human breast 
carcinomas where STAT5a was not expressed.
The prolactin-JAK/STAT pathway is necessary 
for normal breast development and its possible 
involvement in breast oncogenesis is intriguing. 
The changes seen in this study in the reciprocal 
STAT5a/PRLR relationship with breast carcinoma 
may be due to signaling defects in this pathway. 
In normal cells, the nuclear location of STAT5a 
may provide evidence of its activation, as activation 
generally causes STAT5a to accumulate in the 
nucleus (Iyer and Reich, 2007). Combined with 
the over-expression of PRLR, lack of detectable 
STAT5a in the nuclei of in situ and invasive ductal 
carcinoma suggests the possibility of attempted 
STAT5a activation that has been inhibited. Abnor-
malities that could result in abundant PRLR and 
undetectable STAT5a include STAT5a mutations 
that produce a truncated, non-functional version 
(leading to constitutive PRLR expression) 
(Kazansky et al. 1995; Mui et al. 1995) and PRLR 
mutations incapable of activating STAT5a (result-
ing in over-accumulation of PRLR, as is the case 
with p53 mutations). While PRLR gene mutations 
have yet to be identiﬁ  ed in the majority of breast 
cancers (Glasow et al. 2001), they exist in some 
patients (Canbay et al. 2004) and PRLR expression 
has been implicated in breast oncogenesis 
(Clevenger et al. 2003; Gill et al. 2001). Since 
PRLR exists in several functional isoforms 
(Clevenger et al. 2003; Reynolds et al. 1997; 
Trott et al. 2003) and the breast’s endogenous 
prolactin can amplify hormonal effects by up-
regulating speciﬁ  c PRLR isoforms (Clevenger 
et al. 2003; Gutzman et al. 2004), these isoforms 
may interact differently with STAT5a. Recently, 
the demonstration of impaired PRLR degradation 
in breast tumors correlated with enhanced PRLR 
expression (Li et al. 2006).
Different forms of prolactin also have different 
effects on downstream signaling (Wu et al. 2003), 
and prolactin regulates a variety of transcription 
factors and other proteins affecting proliferation, 
such as AP-1, insulin like growth factor 2 and 
pim-1 (Borg et al. 1999; Brisken et al. 2002; 
Gutzman et al. 2005).
Other proteins related to PRLR-STAT signaling 
also may be involved. Post-transcriptional mecha-
nisms down-regulate STAT5a through both the 
protein inhibitors of activated STATs (PIAS) and 13
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the suppressors of cytokine signaling (SOCS) 
proteins (Kotaja et al. 2000; Martens et al 2005). 
The tyrosine phosphatase SHP-2 has been shown 
to regulate the interaction of JAK2 and SOCS1 
(Ali et al. 2003), and JAK2 itself, along with 
C/EBPbeta, can interfere with prolactin/STAT5 
signaling (Grimm et al. 2002; Wagner et al. 2004). 
Also, while PRLR does not require an intact cyto-
skeleton for initial phosphorylation, cytoskeletal 
integrity is necessary to transduce signals from 
PRLR to STAT5a (Zoubiane et al. 2004). Recently 
it was shown that STAT5a could be epigenetically 
silenced by the tyrosine kinase NPM1-ALK result-
ing in the lack of reciprocal inhibition of this 
oncogenic kinase by STAT5a providing some 
evidence of a possible tumor suppression function 
for STAT5a (Zhang et al. 2007).
Intriguingly, secretory carcinomas of the breast 
retain the STAT5a expression seen in normal breast 
epithelium. As described previously, this could be 
due to retention of transcription factors that are lost 
during the development of other types of breast 
cancers, or related to a speciﬁ  c translocation others 
have described in secretory carcinomas, t(12; 15) 
(Tognan et al. 2002), that results in the fusion protein 
ETV6-Ntrk3 possibly activating STAT5a. Regardless 
of the reason for continued STAT5a expression, 
secretory carcinomas are similar to other STAT5a 
positive tissues in showing reduced PRLR expres-
sion. It may therefore be useful to compare the 
involvement of the prolactin-JAK/STAT pathway in 
secretory and non-secretory types of breast cancer.
In summary, STAT5a and PRLR show a 
reciprocal pattern of expression between normal 
and abnormal breast tissues. Reversal of the 
expression seen in normal cells in DCIS and 
invasive carcinoma, resulting in increased PRLR 
and decreased STAT5a, may indicate a signaling 
pathway disturbance and possibly a divergence 
related to carcinogenesis. Further investigation will 
be required to understand the mechanisms by 
which this may occur.
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